334 related articles for article (PubMed ID: 24726460)
1. Targeting receptor-activator of nuclear kappaB ligand in aneurysmal bone cysts: verification of target and therapeutic response.
Pelle DW; Ringler JW; Peacock JD; Kampfschulte K; Scholten DJ; Davis MM; Mitchell DS; Steensma MR
Transl Res; 2014 Aug; 164(2):139-48. PubMed ID: 24726460
[TBL] [Abstract][Full Text] [Related]
2. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.
Branstetter DG; Nelson SD; Manivel JC; Blay JY; Chawla S; Thomas DM; Jun S; Jacobs I
Clin Cancer Res; 2012 Aug; 18(16):4415-24. PubMed ID: 22711702
[TBL] [Abstract][Full Text] [Related]
3. Aneurysmal bone cysts: denosumab extends its reach.
Purdue E
Transl Res; 2014 Aug; 164(2):135-8. PubMed ID: 24837849
[No Abstract] [Full Text] [Related]
4. Receptor-Activator of Nuclear KappaB Ligand Expression as a New Therapeutic Target in Primary Bone Tumors.
Yamagishi T; Kawashima H; Ogose A; Ariizumi T; Sasaki T; Hatano H; Hotta T; Endo N
PLoS One; 2016; 11(5):e0154680. PubMed ID: 27163152
[TBL] [Abstract][Full Text] [Related]
5. RANK signalling in bone lesions with osteoclast-like giant cells.
Won KY; Kalil RK; Kim YW; Park YK
Pathology; 2011 Jun; 43(4):318-21. PubMed ID: 21532526
[TBL] [Abstract][Full Text] [Related]
6. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
[TBL] [Abstract][Full Text] [Related]
7. Receptor activator for NF-κB ligand in acute myeloid leukemia: expression, function, and modulation of NK cell immunosurveillance.
Schmiedel BJ; Nuebling T; Steinbacher J; Malinovska A; Wende CM; Azuma M; Schneider P; Grosse-Hovest L; Salih HR
J Immunol; 2013 Jan; 190(2):821-31. PubMed ID: 23241893
[TBL] [Abstract][Full Text] [Related]
8. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
[TBL] [Abstract][Full Text] [Related]
9. RANKL inhibition in the treatment of bone metastases.
Lipton A; Jun S
Curr Opin Support Palliat Care; 2008 Sep; 2(3):197-203. PubMed ID: 18685421
[TBL] [Abstract][Full Text] [Related]
10. Response of Aneurysmal Bone Cyst to Denosumab.
Skubitz KM; Peltola JC; Santos ER; Cheng EY
Spine (Phila Pa 1976); 2015 Nov; 40(22):E1201-4. PubMed ID: 26730528
[TBL] [Abstract][Full Text] [Related]
11. Receptor activator of nuclear factor-kappaB ligand (RANKL) directly modulates the gene expression profile of RANK-positive Saos-2 human osteosarcoma cells.
Mori K; Berreur M; Blanchard F; Chevalier C; Guisle-Marsollier I; Masson M; Rédini F; Heymann D
Oncol Rep; 2007 Dec; 18(6):1365-71. PubMed ID: 17982618
[TBL] [Abstract][Full Text] [Related]
12. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
[TBL] [Abstract][Full Text] [Related]
13. Receptor activator of nuclear factor-κB ligand is a novel inducer of myocardial inflammation.
Ock S; Ahn J; Lee SH; Park H; Son JW; Oh JG; Yang DK; Lee WS; Kim HS; Rho J; Oh GT; Abel ED; Park WJ; Min JK; Kim J
Cardiovasc Res; 2012 Apr; 94(1):105-14. PubMed ID: 22298642
[TBL] [Abstract][Full Text] [Related]
14. Denosumab Therapy in the Management of Aneurysmal Bone Cysts: A Comprehensive Literature Review.
Alhumaid I; Abu-Zaid A
Cureus; 2019 Jan; 11(1):e3989. PubMed ID: 30972268
[TBL] [Abstract][Full Text] [Related]
15. Targeting RANKL in breast cancer: bone metastasis and beyond.
Azim H; Azim HA
Expert Rev Anticancer Ther; 2013 Feb; 13(2):195-201. PubMed ID: 23406560
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue.
Lau YS; Sabokbar A; Gibbons CL; Giele H; Athanasou N
Hum Pathol; 2005 Sep; 36(9):945-54. PubMed ID: 16153456
[TBL] [Abstract][Full Text] [Related]
17. Fos plays an essential role in the upregulation of RANK expression in osteoclast precursors within the bone microenvironment.
Arai A; Mizoguchi T; Harada S; Kobayashi Y; Nakamichi Y; Yasuda H; Penninger JM; Yamada K; Udagawa N; Takahashi N
J Cell Sci; 2012 Jun; 125(Pt 12):2910-7. PubMed ID: 22454522
[TBL] [Abstract][Full Text] [Related]
18. CD14- mononuclear stromal cells support (CD14+) monocyte-osteoclast differentiation in aneurysmal bone cyst.
Taylor RM; Kashima TG; Hemingway FK; Dongre A; Knowles HJ; Athanasou NA
Lab Invest; 2012 Apr; 92(4):600-5. PubMed ID: 22330339
[TBL] [Abstract][Full Text] [Related]
19. Denosumab for the treatment of giant cell tumor of the bone.
Brodowicz T; Hemetsberger M; Windhager R
Future Oncol; 2015; 11(13):1881-94. PubMed ID: 26161925
[TBL] [Abstract][Full Text] [Related]
20. [Control of bone resorption by RANKL-RANK system].
Harada S; Takahashi N
Clin Calcium; 2011 Aug; 21(8):1121-30. PubMed ID: 21814016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]